56k a year! 

Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO

The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the t
Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet